DexCom: The Great Potential in the Diabetes Market

DexCom's decision to target the type 2 diabetes market was not flawed. The issue lay in the execution of the strategy by the management. Sometimes, the best way to fix a mistake is to double down on it, and that's exactly what DexCom is doing with its continuous glucose monitoring devices for diabetes patients. A decision that should pay off for shareholders. The costly mistake and its consequences Last year, DexCom made a costly mistake. The San Diego-based manufacturer of glucose monitoring devices for people with diabetes decided to shift...